4/A: Galectin Therapeutics Director Kary Eldred Amends Ownership Disclosure After Recent Stock Purchase

Kary Eldred, a director at Galectin Therapeutics, amended a previous SEC filing to reflect a recent purchase of 400 shares of common stock at $2.39 per share.

Summary

• Kary Eldred, a director of Galectin Therapeutics, filed an amended Form 4 with the SEC.
• The amendment relates to a transaction on July 22, 2024, where Eldred purchased 400 shares of Galectin Therapeutics common stock at a price of $2.39 per share.
• Following the reported transaction, Eldred directly owns 49,713 shares of common stock.
• Eldred also indirectly owns 2,425 shares as UTMA custodian for a minor child and 2,000 shares held in trust.
• The reporting person disclaims beneficial ownership of these securities held as custodian or in trust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Industry Context

This filing is a routine disclosure required by the SEC when a company insider, such as a director, buys or sells shares of their company's stock. It provides transparency to the market regarding insider transactions.

Stakeholder Impact

• The transaction provides information to shareholders regarding the actions of a company director.

Key Dates